{"schema_version":"secwatch.filing_event.v1","accession":"0001367644-25-000087","form_type":"8-K","ticker":"EBS","cik":"0001367644","company_name":"Emergent BioSolutions Inc.","filed_at":"2025-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.444770+00:00","generated_at":"2026-05-24T01:36:57.805806+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Emergent BioSolutions authorizes $50M share repurchase program through March 2026","bullets":["Board authorized repurchase of up to $50 million of common stock on or before March 27, 2026.","CEO Joe Papa cites confidence in strategy, future outlook and cash generation as rationale.","Company had approximately 54.3 million shares outstanding as of December 31, 2024.","Repurchases may be made on open market or in private transactions; timing subject to market conditions."],"urls":{"canonical":"https://secwatch.observer/filing/0001367644-25-000087","json":"https://secwatch.observer/filing/0001367644-25-000087.json","markdown":"https://secwatch.observer/filing/0001367644-25-000087.md","text":"https://secwatch.observer/filing/0001367644-25-000087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000087/0001367644-25-000087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1367644/000136764425000087/ebs-20250331.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T01:36:57.805806+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}